

CHI St. Alexius Health Bismarck Inpatient Antibioqram (% Susceptible)														January 1 – December 31, 2021																							
ORGANISMS- <i>INPATIENT</i> isolates		Isolates Tested	PCN G IV (nonmeningitis)	PCN (meningitis and PO dosing)	Ampicillin	Oxacillin	Amoxacillin/ clavulanic acid ¹	Piperacillin/tazobactam	Cefazolin (non-urine)	Cefazolin (urine)	Ceftriaxone (non-meningitis)	Ceftriaxone (meningitis)	Cefepime ¹	Meropenem	Gentamicin	Tobramycin	Levofloxacin	Ciprofloxacin	Vancomycin	Clindamycin	Azithromycin	TMP/SMX	Doxycycline	Nitrofurantoin (urine isolates only)													
Gram-positive	Staph aureus (MSSA)	136				100									99		86		100	73	67	99	99	100													
	Staph aureus (MRSA)	71													96				100	70		100	97	100													
	Staph aureus (All strains)	214				67			67						98		71		100	64	44	100	99	100													
	Staph coag negative	70				46			46						91		81		99	62	39	73	89	100													
	Strep pneumoniae	24	96	67							92	79					96		100		48	78	30														
	Strep viridans	52	75									94						90		100	82	42															
	Enterococcus species	154			89											77 ³		74	72	92					89												
Gram-negative	Haemophilus influenzae	7			86						100						100				100		71														
	E. coli	581					86	97		94	96		97	100		96	87	87					86		98												
	Klebsiella pneumoniae	157					96	96		95	96		98	99		98	98	97				94															
	Klebsiella oxytoca	27					100	100			100		100	100		100	96	96				100		85													
	Proteus mirabilis	61					100	100		98	98		98	100		98	84	82				92															
	Enterobacter cloacae	49						74					94	96		96	94	96				88		39													
	Kleb (Enterobacter) aerogenes	19						74					100	100		100	100	100				95															
	Citrobacter freundii	8						100			88		100	100			100	100				100		100													
	Pseudomonas aeruginosa ²	81						86					90	85			98	79	81																		
	⁵ – Gentamicin synergy only ¹ – Ampicillin/sulbactam and Ceftazidime no longer routinely tested ² -- Pseudomonas data does not include CF isolates ESBL rate decreased 4% to 3.4%. Rifampin is 100% susceptible against all Staph aureus strains. Use only as adjunct to main therapy. For more information, contact: NPL Micro Dept: 530-5733 Pharmacy Dept: 530-6914																																				
= DO NOT USE WITHOUT SUSCEPTIBILITY RESULTS, OR <80%														= NOT APPLICABLE, OR <30% SUSCEPTIBLE														= Not Tested									

For CLINIC use only-CHI St. Alexius Health Antibiogram (% Susceptible)																			January 1 – December 31, 2021				
	ORGANISMS – CLINIC isolates only	Isolates Tested	PCN G (nonmeningitis)	Ampicillin	Oxacillin	Amoxicillin/Clavulanic Acid	Piperacillin/tazobactam	Cefazolin (non-urine)	Cefazolin (urine)	Ceftriaxone (nonmeningitis)	Ceftriaxone (meningitis)	Cefepime	Meropenem	Gentamicin	Tobramycin	Levofloxacin	Ciprofloxacin	Vancomycin	Clindamycin	Azithromycin	TMP/SMX	Doxycycline	Nitrofurantoin (urine isolates only)
Gram-positive	Staph aureus (All strains)	149			74									100		76		100	76	55	97	99	100
	Staph coag negative	93			47									95		76		100	67		79	82	100
	Strep pneumoniae	2																					
	Strep viridans	24	96							100						96		100	79	54			
	Enterococcus species	102		97										91 ^s		87	84	98				36	92
Gram-negative	Haemophilus influenzae	2																					
	E. coli	519				88	98		95	97		98	100		96	90	90					85	98
	Klebsiella pneumoniae	74				97	96		97	97		97	100		99	97	97				88		30
	Klebsiella oxytoca	20				95	100			100		100	100		100	100	100				95		100
	Proteus mirabilis	33				100	100		97	97		100	100		94	85	79				91		
	Enterobacter cloacae	32					90					97	100		100	97	97				88		46
	Serratia marcescens	11								100		100	91		100	91	91				100		
	Kleb (Enterobacter) aerogenes	17					71			71		100	100		100	100	100				100		
	Citrobacter freundii	12					100			100		100	100		92	92	92				83		100
	Pseudomonas aeruginosa	39					85					95	82		95	74	82						

^s – Gentamicin synergy
 Monotherapy with amoxicillin or nitrofurantoin may be used for enterococcal UTIs.
 Rifampin is 99% susceptible against all Staph aureus strains. Use only as adjunct to main therapy.

= DO NOT USE WITHOUT SUSCEPTIBILITY RESULTS, OR <80%
 = NOT APPLICABLE, OR <30% SUSCEPTIBLE
 = not tested
 = low # of isolates tested may skew susceptibility data, see inpatient antibiogram

If you have any questions or need any additional information, contact:
 NPL Microbiology Department
 530-5700
 Pharmacy Department
 530-6914